» » »

Commercial Genetic Tests Durham NC

According to Dr. Muin J. Khoury, director of the Office of Public Health Genomics at the U.S. Centers for Disease Control and Prevention, some 1,800 to 2,000 genetic tests have been developed, most of which are relevant only to rare genetic conditions that don't affect too many people.

Maria J Small
(919) 684-8111
1000 Trent Drive
Durham, NC
Specialty
Obstetrics & Gynecology

Data Provided by:
Audrey Anita Romero, MD
(505) 272-6383
Trent Drive,
Durham, NC
Specialties
Obstetrics & Gynecology
Gender
Female
Education
Medical School: Hahnemann Univ Sch Of Med, Philadelphia Pa 19102
Graduation Year: 1996

Data Provided by:
Richard Auten
(919) 620-4467
2100 Erwin Rd
Durham, NC
Specialty
Neonatal-Perinatal Medicine

Data Provided by:
James Lawrence Wynn
(919) 684-8111
2100 Erwin Rd
Durham, NC
Specialty
Neonatal-Perinatal Medicine

Data Provided by:
Katrina Howard Avery, MD
(919) 967-8052
Trent Drive,
Durham, NC
Specialties
Obstetrics & Gynecology
Gender
Female
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1991

Data Provided by:
Craig Joseph Sobolewski, MD
(919) 684-4647
Duke Hospital South Trent Drive,
Durham, NC
Specialties
Obstetrics & Gynecology
Gender
Male
Education
Medical School: Oh State Univ Coll Of Med, Columbus Oh 43210
Graduation Year: 1992
Hospital
Hospital: Duke University Med Ctr, Durham, Nc

Data Provided by:
Ronald Goldberg
(919) 620-4467
2100 Erwin Rd
Durham, NC
Specialty
Neonatal-Perinatal Medicine

Data Provided by:
Diana Dell
(919) 620-4467
Duke University Medical Ctr
Durham, NC
Specialty
Obstetrics & Gynecology

Data Provided by:
Eleanor Hoon Joo Rhee, MD
(919) 681-3507
Duke Univ Med Ctr
Durham, NC
Specialties
Obstetrics & Gynecology
Gender
Female
Education
Medical School: Yale Univ Sch Of Med, New Haven Ct 06510
Graduation Year: 1998

Data Provided by:
Evan Myers
(919) 620-4467
2100 Erwin Rd
Durham, NC
Specialty
Obstetrics & Gynecology

Data Provided by:
Data Provided by:

Commercial Genetic Tests

Provided By:

WEDNESDAY, Oct. 14 (HealthDay News) -- Peter Orszag, the 40-year-old head of the White House Office of Management and Budget, is reported to drink so much tea, hot and iced, that he took a genetic test to see if his body could metabolize his voluminous intake of caffeine.

According to the results, his body is perfectly suited to the task, and Orszag can easily go about his busy day, according to published reports.

Like Orszag, droves of people are flocking to get genetic tests -- which are now marketed direct-to-consumer -- ranging from the $179 CaffeineGen to assess caffeine metabolism to those that claim to gauge risk for Alzheimer's disease. There's also a $79 HomeDNA Home Paternity Testing System that includes, for an additional $25, lab services for the "alleged" father and one child.

But whether or not the commercially available genetic tests currently entering the market actually provide any useful information is another question.

According to Dr. Muin J. Khoury, director of the Office of Public Health Genomics at the U.S. Centers for Disease Control and Prevention, some 1,800 to 2,000 genetic tests have been developed, most of which are relevant only to rare genetic conditions that don't affect too many people.

"A growing number of these tests are suggested to be used to target interventions [pharmacogenetics], and to do early detection or susceptibility testing," Khoury said.

Khoury participated in a recent conference hosted by the National Academy of Sciences in Washington, D.C., that looked at direct-to-consumer marketing of genetic tests. Among other things, panelists discussed how valid and useful these tests are. Probably some will prove useful, and some will not, the experts said.

"With very few exceptions, we still have some big gaps in evidence," said Dr. Marc S. Williams, director of clinical genetics at the American College of Medical Genetics and director of Intermountain Healthcare, Clinical Genetics Institute, in Salt Lake City. "Do we really know if this works or not?"

"We don't know what they do to help people or hurt them," Khoury added.

Some are tried and true, such as those to detect the BRCA 1 and 2 genes, which heighten a woman's risk for breast and ovarian cancer, or specific tests to figure the risk for Lynch syndrome, a hereditary form of colon cancer.

But take the example of several much-hyped genetic tests to help determine what type or what dose of antidepressant would be effective for different individuals.

"Researchers have found that even clinically available tests that are supposed to inform someone about specific doses or specific medications use virtually no evidence. We don't even know what to do with the results of tests in terms of dosing, etcetera," Williams said. "People are promoting this test to choose which SSRI [selective serotonin reuptake inhibitor] they should use and at what dose with almost no evidence. We'd love to be able to predict which drug to use, but the evidence just isn't there to support that."

And results could be alarming to some people, said Sandra Soo-Jin Lee, senior research scholar and medical anthropologist at the Stanford University Center for Biomedical Ethics, although one recent study reported that people who discovered they had a higher risk for Alzheimer's through a genetic test were not psychologically distressed by the results.

Perhaps they kept in mind that genes are only one factor that determine risk. The environment also has a lot to do with it.

For instance, "there is a fairly robust history of research around genetic variations a population might express in terms of how they take up those chemicals. So, in terms of caffeine metabolism, there may be some individuals that are fast metabolizers of caffeine so it goes through their system fairly quickly," Lee said.

"But there may also be other things about that person and that person's environment that affect how they metabolize caffeine. For now, we just don't know what's what in terms of tests and results," she added.

"Right now, the direct-to-consumer genetic testing companies are working in an unregulated space. It's sort of a no man's land," Lee said. "But I think there are some indications that we are moving in a direction of creating some hopeful policies. One of the first steps is making sure all the stakeholders come together and discuss what would be helpful in terms of regulation. That not only means health-care providers and patients, but companies themselves."

Attempts by HealthDay to reach several makers of the tests for comment were unsuccessful.

More information

The U.S. National Library of Medicine has more on genetic testing.

Author: By Amanda Gardner
HealthDay Reporter

SOURCES: Muin J. Khoury, M.D., Ph.D., director, Office of Public Health Genomics, U.S. Centers for Disease Control and Prevention, Atlanta; Marc S. Williams, M.D., director, clinical genetics, American College of Medical Genetics, and director, Intermountain Healthcare, Clinical Genetics Institute, Salt Lake City, Utah; Sandra Soo-Jin Lee, Ph.D., senior research scholar and medical anthropologist, Stanford University Center for Biomedical Ethics, Palo Alto, Calif.; March 27, 2009, The New York Times

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com